Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer
  2. Aide
  2. Aide
SEP 25 CAC 40 Index (10x)
7 722,00
+0,76%
Indices
Chiffres-clés
+ fortes hausses et baisses SBF 120

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
information fournie par Boursorama CP 18/01/2022 à 17:45

Collaboration to Evaluate the Combination of Transgene’s Oncolytic Virus and PersonGen’s CAR-T Cells in Preclinical Models

Strasbourg, France, and Suzhou, China, January 18, 2022, 5:45 pm CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and PersonGen BioTherapeutics, a Chinese biotech company at clinical trial stage, which is developing breakthrough and innovative CAR-T cell therapies for solid tumors and hematologic tumors, today announced a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating PersonGen's TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgene’s Invir.IO™ platform, in solid tumors including pancreatic cancer and brain glioma. The collaboration aims to demonstrate the combination’s likely synergistic mechanisms to potentiate CAR-T cell therapy.

.../...

Valeurs associées

TRANSGENE
1,1250 EUR Euronext Paris +1,81%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank